ArticleNature communications2026
Selenium atom transfer enables selective bridged alkene-arylamine cycloaddition.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cycloaddition reactions are central to building cyclic molecular architectures for drug discovery and materials science. However, controlling single-atom-bridged cycloaddition remains elusive. Herein, we describe a selenium-atom transfer [3 + 2 + 1] heterocycloaddition of readily available arylamines, alkenes and diselenides, enabling rapid, modular access to diverse selenium- and nitrogen-containing heterocycles, including selenomorpholines and polycyclic 1,4-selenazinanes. This metal-free method operates under mild, simple conditions with scalability, showcasing broad substrate generality and functional group tolerance, is amenable to scalable synthesis, and demonstrates utility in the late-stage skeletal diversification of complex molecules. Mechanistic and computational studies reveal a Se-bridged cycloaddition pathway involving alkene aminoselenylation, followed by electrophilic selenocyclization and deprotonative rearomatization. This heteroatom-driven annulation opens opportunities for the development of reactions for the construction of multi-heteroatom cyclic scaffolds and broader application in selenium-based medicinal chemistry.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.